浙江大洋生物科技集团股份有限公司 2025 年第三季度报告 证券代码：003017 证券简称：大洋生物 公告编号：2025-095 浙江大洋生物科技集团股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： | | 本报告期 | 本报告期比上年同期 | 年初至报告期末比上 年初至报告期末 | | | --- | --- | --- | --- | --- | | | | 增减 | 年同期增减 | | | 营业收入（元） | 247,995,033.65 | 5.72% | 747,305,412.73 | 11.24% | | 归属于上市公司股东 | 29,531,000.73 | 48.92% | 80,036,566.00 | 56.12% | | 的净利润（元） | | | | | | 归属于上市公司股东 的扣除非经常性损益 | 28,222,654.83 | 47.79% | 74,983,571.02 | 55.61% | | 的净利润（元） | | | | | | 经营活动产生的现金 | — | — | ...

Group 1 - The company announced a cash dividend distribution plan for the first half of 2025, proposing to pay 3 RMB per 10 shares to all shareholders, including tax [2] - The record date for the dividend distribution is set for October 23, 2025, while the ex-dividend date is October 24, 2025 [2]

股权登记日2025年10月23日，现金红利发放日2025年10月24日。 格隆汇10月17日丨大洋生物(003017.SZ)发布2025年半年度权益分派实施公告，以公司现有总股本8400 万股为基数，向全体股东每股派0.3元人民币现金（含税；扣税后，通过深股通持有股份的香港市场投 资者、境外机构（含 QFII、RQFII）以及持有首发前限售股的个人和证券投资基金每股派0.27元。 ...

证券代码：003017 证券简称：大洋生物 公告编号：2025-093 浙江大洋生物科技集团股份有限公司 2025 年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、股东大会审议通过的权益分派方案情况 公司于 2025 年 9 月 12 日召开的 2025 年第二次临时股东大会审议通过了《关 于 2025 年半年度利润分配预案的议案》，具体内容详见公司 2025 年 8 月 26 日 在《证券时报》《证券日报》和巨潮资讯网（http://www.cninfo.com.cn）上披露 的《关于 2025 年半年度利润分配预案的公告》（公告编号：2025-079）。 1.公司以总股本 84,000,000 股为基数，向全体股东每 10 股派发现金红利 3.00 元（含税），上述利润分配后，剩余未分配利润结转至下一年度再行分配。公司 2025 年半年度不送红股，不以资本公积金转增股本。 2.本次实施的权益分派方案披露至实施期间公司股本总额未发生变化。 3.本次实施的权益分派方案与公司 2025 年第二次临时股东大会审议通过的 权益分派方案一 ...

Core Insights - The article highlights significant year-on-year profit growth for various companies in the first three quarters, with some reporting exceptionally high increases in net profit [1] Group 1: Companies with Exceptional Profit Growth - Xinda Co., Ltd. expects a net profit increase of 2807.87%-3211.74% year-on-year [1] - Shenghe Resources anticipates a net profit growth of 696.82%-782.96% year-on-year [1] - Jiantou Energy projects a net profit rise of 231.75% year-on-year [1] - Batian Co., Ltd. forecasts a net profit increase of 230.79%-260.15% year-on-year [1] - Bai'ao Intelligent expects a net profit growth of 158.04%-210.20% year-on-year [1] Group 2: Companies with Notable Profit Increases - Tongxing Technology anticipates a net profit increase of 154.30%-233.77% year-on-year [1] - Ruixin Microelectronics projects a net profit growth of 116%-127% year-on-year [1] - Yahua Group expects a net profit increase of 106.97%-132.84% year-on-year [1] - Suihengyun A anticipates a net profit rise of 87.83%-180.38% year-on-year [1] - Taishan Petroleum projects a net profit increase of 87%-125% year-on-year [1] Group 3: Companies with Moderate Profit Growth - Shandong Gold anticipates a net profit increase of 83.9%-98.5% year-on-year [1] - Lutai A expects a net profit growth of 70.23%-84.12% year-on-year [1] - Zongshen Power projects a net profit increase of 70%-100% year-on-year [1] - Zijang Enterprises anticipates a net profit rise of 70%-90% year-on-year [1] - Jinjiang Shipping expects a net profit increase of 62.72%-66.89% year-on-year [1] Group 4: Companies with Lower but Positive Profit Growth - Jieshun Technology anticipates a net profit increase of 58.11%-86.01% year-on-year [1] - Gibit expects a net profit growth of 57%-86% year-on-year [1] - Xindong Link expects a net profit increase of 56.43%-91.19% year-on-year [1] - Tongda Co., Ltd. (rights protection) anticipates a net profit increase of 50.01%-111.12% year-on-year [1] - Dongwu Securities projects a net profit growth of 50%-65% year-on-year [1] Group 5: Companies Reporting Turnaround - Yuanda Intelligent (rights protection) expects a net profit of 33.83 million to 50.73 million, marking a turnaround [1] - Luoxin Pharmaceutical (rights protection) anticipates a net profit of 22.70 million to 25.20 million, indicating a turnaround [1] - Zhongke Sanhuan expects a net profit of 80 million to 100 million, also indicating a turnaround [1]

证券日报网讯 10月14日晚间，大洋生物发布2025年前三季度业绩预告称，公司预计2025年前三季度归 属于上市公司股东的净利润为7，400万元—9，000万元，比上年同期增长44.35%—75.56%。 （编辑 任世碧） ...

Core Viewpoint - The company expects a significant increase in net profit for the first three quarters, driven by higher demand for its main products, potassium carbonate and veterinary raw materials, resulting in increased sales and prices [1] Financial Performance - The net profit attributable to shareholders is projected to be between 74 million and 90 million yuan, representing a year-on-year growth of 44.35% to 75.56% [1] - The net profit after deducting non-recurring gains and losses is expected to be between 67 million and 82 million yuan, indicating a year-on-year increase of 39.04% to 70.17% [1] Market Influence - The increase in net profit is primarily attributed to market influences that have boosted the demand for the company's main products [1] - Both sales volume and prices have risen compared to the same period last year, contributing to an increase in gross profit margin [1]

Core Viewpoint - The company, Dayang Bio (003017.SZ), anticipates a significant increase in net profit for the first three quarters of 2025, driven by rising demand for its main products, potassium carbonate and veterinary raw materials [1] Financial Performance - The company expects net profit attributable to shareholders to be between 74 million and 90 million yuan, representing a year-on-year growth of 44.35% to 75.56% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 67 million and 82 million yuan, indicating a year-on-year increase of 39.04% to 70.17% [1] Market Influence - The increase in net profit is primarily attributed to market influences that have boosted the demand for the company's main products [1] - Both sales volume and prices of potassium carbonate and veterinary raw materials have risen compared to the same period last year, contributing to the improved gross margin [1]

Core Viewpoint - The company, Dayang Bio (003017.SZ), anticipates a significant increase in net profit for the first three quarters of 2025, driven by rising demand for its main products, potassium carbonate and veterinary raw materials [1] Financial Performance - The company expects net profit attributable to shareholders to be between 74 million and 90 million yuan, representing a year-on-year growth of 44.35% to 75.56% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 67 million and 82 million yuan, indicating a year-on-year increase of 39.04% to 70.17% [1] Market Factors - The increase in net profit is primarily attributed to market influences that have boosted the demand for the company's main products [1] - Both sales volume and prices of potassium carbonate and veterinary raw materials have risen compared to the same period last year, contributing to the improved gross margin [1]

Core Viewpoint - The company, Dayang Biological (003017.SZ), expects a significant increase in net profit for the first three quarters, driven by rising demand for its main products, potassium carbonate and veterinary raw materials, due to market influences [1] Financial Performance - The net profit attributable to shareholders is projected to be between 74 million and 90 million yuan, representing a year-on-year growth of 44.35% to 75.56% [1] - The net profit after deducting non-recurring gains and losses is expected to be between 67 million and 82 million yuan, indicating a growth of 39.04% to 70.17% compared to the same period last year [1] Market Dynamics - The increase in net profit is attributed to higher sales volumes and prices of the company's main products, along with an improvement in gross profit margins [1]